miRecule, Inc.
miRecule is a biotechnology company dedicated to developing RNA therapies for cancer and muscular dystrophy. Utilizing their proprietary DREAmiR™ platform, they create highly tailored therapeutics based on genomic patient data, aiming to help patients live symptom-free lives. Their approach involves identifying genetic abnormalities and designing RNA therapeutics that directly target and correct these issues, with a focus on personalized medicine and targeted delivery to diseased tissues.
Industries
Nr. of Employees
small (1-50)
Products
Genomics-based RNA discovery platform
An analytics platform that integrates genomic sequencing and clinical outcomes to nominate and prioritize RNA targets for therapeutic development.
Engineered oligonucleotide therapeutics (preclinical candidates)
Chemically modified RNA/oligonucleotide drug candidates designed for enhanced binding, stability, and therapeutic activity against disease-relevant RNA targets (preclinical-stage).
Antibody–oligonucleotide conjugate therapeutic (program licensed to partner)
A muscle-targeted antibody–oligonucleotide conjugate developed to suppress a disease-causing gene in facioscapulohumeral muscular dystrophy; candidate selection and early development were performed prior to exclusive licensing to a pharmaceutical partner for IND-enabling and clinical development.
Genomics-based RNA discovery platform
An analytics platform that integrates genomic sequencing and clinical outcomes to nominate and prioritize RNA targets for therapeutic development.
Engineered oligonucleotide therapeutics (preclinical candidates)
Chemically modified RNA/oligonucleotide drug candidates designed for enhanced binding, stability, and therapeutic activity against disease-relevant RNA targets (preclinical-stage).
Antibody–oligonucleotide conjugate therapeutic (program licensed to partner)
A muscle-targeted antibody–oligonucleotide conjugate developed to suppress a disease-causing gene in facioscapulohumeral muscular dystrophy; candidate selection and early development were performed prior to exclusive licensing to a pharmaceutical partner for IND-enabling and clinical development.
Services
Genomics-based discovery and patient stratification
Identification of RNA therapeutic targets by integrating genomic sequencing with clinical outcome data to define patient subsets for targeted therapies.
Preclinical development and translational biomarker programs
In vitro and in vivo pharmacology, mechanism-of-action studies, biomarker development, and bioanalytical support to advance programs toward candidate selection.
Conjugation and targeted delivery development
Development of antibody–oligonucleotide conjugation methods and formulations to enable tissue-selective delivery of RNA therapeutics.
Licensing and strategic partnership development
Negotiation and execution of exclusive licenses and collaborations with industry partners to advance development and commercialization.
Genomics-based discovery and patient stratification
Identification of RNA therapeutic targets by integrating genomic sequencing with clinical outcome data to define patient subsets for targeted therapies.
Preclinical development and translational biomarker programs
In vitro and in vivo pharmacology, mechanism-of-action studies, biomarker development, and bioanalytical support to advance programs toward candidate selection.
Conjugation and targeted delivery development
Development of antibody–oligonucleotide conjugation methods and formulations to enable tissue-selective delivery of RNA therapeutics.
Licensing and strategic partnership development
Negotiation and execution of exclusive licenses and collaborations with industry partners to advance development and commercialization.
Expertise Areas
- RNA therapeutic discovery
- Antibody–oligonucleotide conjugates and targeted delivery
- Genomics-driven patient stratification
- Preclinical pharmacology and biodistribution
Key Technologies
- Patient genomics integration and outcome analytics
- High-throughput cell-based screening
- Chemically modified oligonucleotide design
- Antibody–oligonucleotide conjugation chemistry